Monday, 14 March 2011

Human antibody discovery specialist combining yeast and phage technologies

AbCheck sro, the multi antibody discovery platforms company, announced today the company has licensed a proven antibody yeast display technology from CELEXION LLC (Cambridge, MA, USA). The addition of this platform to AbCheck's current phage display platform places the company as the World's only antibody discovery specialist leveraging the advantage of working with both phage and yeast display technologies.

"In our discussions with partners we noticed an increasing demand for human antibodies with not only high affinity and target specificities, but also good drugability and biological functionalities," said Dr. Volker Lang, CEO of AbCheck. "By combining the strength of both yeast and phage technologies into AbSieve we have created a platform that exactly addresses this market need. Moreover, we can combine this with delivery in very competitive timeframes and maximum flexibility to construct generous tailor made deals."

Under the deal terms, AbCheck receives non-exclusive rights to the yeast display platform in the Czech Republic and worldwide rights to commercialize derivative products. Financial terms were not disclosed. The technology has proven to be able to display full length functional IgGs, tandem scFvs and scFvs plus many other non-antibody proteins.

"We are very pleased to partner with the experienced antibody engineering team at AbCheck, and to see our powerful SECANT platform become a key component of their toolbox." said Dr. Brian M. Baynes, CEO of CELEXION.

"In more than 25 projects we have used our phage display antibody technology to identify human antibodies with high affinities and demanding target specificities. I am excited about expanding our capabilities by adding the ability to display antibodies in virtually any format and simultaneously screen for high affinity and drugability to our already efficient technology," stated Dr Vera Molkenthin, CSO of AbCheck. "Now we have the maximum likelihood to identify antibodies with exactly the drug target profile requested by our partners."